2 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 1 | 1 | Unknown 1 |
Follow Hypergammaglobulinemia: new trials by email Literature Review of Hypergammaglobulinemia trials Research Report on Hypergammaglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Isatuximab in Type I Cryoglobulinemia Isatuximab Injection - Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 21 | 2021-11-01 | 2021-11-09 |
| Beta Alethine in Treating Patients With Myeloma beta alethine - Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition | Phase 1 / Phase 2 | Unknown | LifeTime Pharmaceuticals | 2000-08-01 | 2013-12-18 |
Monoclonal Gammopathy of Undetermined Significance (2) · Multiple Myeloma (2) · Cryoglobulinemia, Familial Mixed (1) · Neoplasms, Plasma Cell (1) · Precancerous Conditions (1)
Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Paraproteinemias (2) · Vascular Diseases (2) · Neoplasms, Plasma Cell (1)
alethine (1) · isatuximab (1)
Assistance Publique - Hôpitaux de Paris (1) · LifeTime Pharmaceuticals (1)
United States (1)